Abstract
We urgently need to identify new druggable targets for pediatric cancers. Coutinho etal.1 identified and validated XPO1 aberrant activity in patients with Wilms tumor (WT) and malignant rhabdoid tumor (MRT) using public databases and report an early proof-of-concept bench-to-bedside translation of XPO1 inhibition in pediatric WT and MRT.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have